ID   SMRCD_HUMAN             Reviewed;        1026 AA.
AC   Q9H4L7; B7Z799; Q05D56; Q96SX1; Q9H017; Q9H860; Q9NPU9; Q9ULU7;
DT   28-MAR-2003, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 2.
DT   28-JUN-2023, entry version 194.
DE   RecName: Full=SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A containing DEAD/H box 1;
DE            EC=3.6.4.12;
DE   AltName: Full=ATP-dependent helicase 1;
DE            Short=hHEL1;
GN   Name=SMARCAD1; Synonyms=KIAA1122;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT
RP   ALA-301.
RC   TISSUE=Fetal brain;
RX   PubMed=11031099; DOI=10.1006/geno.2000.6281;
RA   Adra C.N., Donato J.-L., Badovinac R., Syed F., Kheraj R., Cai H.,
RA   Moran C., Kolker M.T., Turner H., Weremowicz S., Shirakawa T., Morton C.C.,
RA   Schnipper L.E., Drews R.;
RT   "SMARCAD1, a novel human helicase family-defining member associated with
RT   genetic instability: cloning, expression, and mapping to 4q22-q23, a band
RT   rich in breakpoints and deletion mutants involved in several human
RT   diseases.";
RL   Genomics 69:162-173(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10574461; DOI=10.1093/dnares/6.5.329;
RA   Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.;
RT   "Characterization of cDNA clones selected by the GeneMark analysis from
RT   size-fractionated cDNA libraries from human brain.";
RL   DNA Res. 6:329-336(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 1-702 (ISOFORMS 1/2), AND NUCLEOTIDE SEQUENCE [LARGE
RP   SCALE MRNA] OF 649-1026 (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS ASN-247;
RP   ALA-301; GLN-351 AND ALA-972.
RC   TISSUE=Kidney, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 433-1026 (ISOFORM 1).
RC   TISSUE=Melanoma, and Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-127; SER-239 AND
RP   SER-242, VARIANT [LARGE SCALE ANALYSIS] ASN-247, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-127; SER-132 AND
RP   SER-302, VARIANT [LARGE SCALE ANALYSIS] ALA-301, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [9]
RP   DNA-BINDING, AND INTERACTION WITH MSH2 AND TRIM28.
RX   PubMed=18675275; DOI=10.1016/j.jmb.2008.07.031;
RA   Okazaki N., Ikeda S., Ohara R., Shimada K., Yanagawa T., Nagase T.,
RA   Ohara O., Koga H.;
RT   "The novel protein complex with SMARCAD1/KIAA1122 binds to the vicinity of
RT   TSS.";
RL   J. Mol. Biol. 382:257-265(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-79; SER-124; SER-127;
RP   SER-132; SER-211 AND SER-214, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-54; SER-124; SER-127; SER-132
RP   AND SER-146, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124 AND SER-127, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   INVOLVEMENT IN ADERM, TISSUE SPECIFICITY, AND ALTERNATIVE SPLICING (ISOFORM
RP   3).
RX   PubMed=21820097; DOI=10.1016/j.ajhg.2011.07.004;
RA   Nousbeck J., Burger B., Fuchs-Telem D., Pavlovsky M., Fenig S., Sarig O.,
RA   Itin P., Sprecher E.;
RT   "A mutation in a skin-specific isoform of SMARCAD1 causes autosomal-
RT   dominant adermatoglyphia.";
RL   Am. J. Hum. Genet. 89:302-307(2011).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH PCNA; TRIM28; HDAC1;
RP   HDAC2; EHMT2; PARP1 AND CBX3, AND MUTAGENESIS OF LYS-528.
RX   PubMed=21549307; DOI=10.1016/j.molcel.2011.02.036;
RA   Rowbotham S.P., Barki L., Neves-Costa A., Santos F., Dean W., Hawkes N.,
RA   Choudhary P., Will W.R., Webster J., Oxley D., Green C.M., Varga-Weisz P.,
RA   Mermoud J.E.;
RT   "Maintenance of silent chromatin through replication requires SWI/SNF-like
RT   chromatin remodeler SMARCAD1.";
RL   Mol. Cell 42:285-296(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-54; SER-57; SER-124; SER-127;
RP   SER-146; SER-152; SER-239 AND SER-242, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [18]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22960744; DOI=10.1038/nature11353;
RA   Costelloe T., Louge R., Tomimatsu N., Mukherjee B., Martini E.,
RA   Khadaroo B., Dubois K., Wiegant W.W., Thierry A., Burma S., van Attikum H.,
RA   Llorente B.;
RT   "The yeast Fun30 and human SMARCAD1 chromatin remodellers promote DNA end
RT   resection.";
RL   Nature 489:581-584(2012).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-71; SER-79; SER-146; SER-152;
RP   SER-211; SER-239 AND SER-302, VARIANT [LARGE SCALE ANALYSIS] ALA-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   INVOLVEMENT IN BSNS.
RX   PubMed=24664640; DOI=10.1002/ajmg.a.36438;
RA   Marks K.C., Banks W.R. III, Cunningham D., Witman P.M., Herman G.E.;
RT   "Analysis of two candidate genes for Basan syndrome.";
RL   Am. J. Med. Genet. A 164A:1188-1191(2014).
RN   [22]
RP   INVOLVEMENT IN ADERM.
RX   PubMed=24909267; DOI=10.1111/bjd.13176;
RA   Nousbeck J., Sarig O., Magal L., Warshauer E., Burger B., Itin P.,
RA   Sprecher E.;
RT   "Mutations in SMARCAD1 cause autosomal dominant adermatoglyphia and perturb
RT   the expression of epidermal differentiation-associated genes.";
RL   Br. J. Dermatol. 171:1521-1524(2014).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-217, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-77, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [25]
RP   INVOLVEMENT IN BSNS.
RX   PubMed=26932190; DOI=10.1038/ejhg.2016.15;
RA   Li M., Wang J., Li Z., Zhang J., Ni C., Cheng R., Yao Z.;
RT   "Genome-wide linkage analysis and whole-genome sequencing identify a
RT   recurrent SMARCAD1 variant in a unique Chinese family with Basan
RT   syndrome.";
RL   Eur. J. Hum. Genet. 24:1367-1370(2016).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-77; LYS-84; LYS-335; LYS-471;
RP   LYS-724 AND LYS-996, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [27]
RP   INVOLVEMENT IN HRZ, AND TISSUE SPECIFICITY.
RX   PubMed=29409814; DOI=10.1016/j.jid.2018.01.015;
RA   Guenther C., Lee-Kirsch M.A., Eckhard J., Matanovic A., Kerscher T.,
RA   Rueschendorf F., Klein B., Berndt N., Zimmermann N., Flachmeier C.,
RA   Thuss T., Lucas N., Marenholz I., Esparza-Gordillo J., Huebner N.,
RA   Traupe H., Delaporte E., Lee Y.A.;
RT   "SMARCAD1 Haploinsufficiency Underlies Huriez Syndrome and Associated Skin
RT   Cancer Susceptibility.";
RL   J. Invest. Dermatol. 138:1428-1431(2018).
RN   [28]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-301, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
CC   -!- FUNCTION: DNA helicase that possesses intrinsic ATP-dependent
CC       nucleosome-remodeling activity and is both required for DNA repair and
CC       heterochromatin organization. Promotes DNA end resection of double-
CC       strand breaks (DSBs) following DNA damage: probably acts by weakening
CC       histone DNA interactions in nucleosomes flanking DSBs. Required for the
CC       restoration of heterochromatin organization after replication. Acts at
CC       replication sites to facilitate the maintenance of heterochromatin by
CC       directing H3 and H4 histones deacetylation, H3 'Lys-9' trimethylation
CC       (H3K9me3) and restoration of silencing. {ECO:0000269|PubMed:21549307,
CC       ECO:0000269|PubMed:22960744}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + H(+) + phosphate; Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.12;
CC   -!- SUBUNIT: Binds to DNA preferentially in the vicinity of transcriptional
CC       start sites. Interacts with MSH2 and TRIM28. Part of a complex composed
CC       of TRIM28, HDAC1, HDAC2 and EHMT2. Interacts with PCNA.
CC       {ECO:0000269|PubMed:18675275, ECO:0000269|PubMed:21549307}.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome. Note=Colocalizes with PCNA
CC       at replication forks during S phase. Recruited to double-strand breaks
CC       (DSBs) sites of DNA damage.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Long;
CC         IsoId=Q9H4L7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H4L7-2; Sequence=VSP_007104;
CC       Name=3; Synonyms=Short;
CC         IsoId=Q9H4L7-3; Sequence=VSP_043110;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed ubiquitously. Isoform 3 is
CC       expressed mainly in skin and esophagus. Expressed in fibroblasts and
CC       keratinocytes (at protein level) (PubMed:29409814).
CC       {ECO:0000269|PubMed:11031099, ECO:0000269|PubMed:21820097,
CC       ECO:0000269|PubMed:29409814}.
CC   -!- DISEASE: Adermatoglyphia (ADERM) [MIM:136000]: An autosomal dominant
CC       condition characterized by the lack of epidermal ridges on the palms
CC       and soles, which results in the absence of fingerprints, and is
CC       associated with a reduced number of sweat gland openings and reduced
CC       sweating of palms and soles. {ECO:0000269|PubMed:21820097,
CC       ECO:0000269|PubMed:24909267}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. Splice site mutations
CC       causing aberrant splicing of skin-specific isoform 3 are likely to
CC       exert a loss-of-function effect and are involved in ADERM.
CC       {ECO:0000269|PubMed:21820097, ECO:0000269|PubMed:24909267}.
CC   -!- DISEASE: Basan syndrome (BSNS) [MIM:129200]: An autosomal dominant form
CC       of adermatoglyphia associated with congenital facial milia, acral
CC       blistering, digital contractures, and nail abnormalities.
CC       Adermatoglyphia is defined by the lack of epidermal ridges on the palms
CC       and soles, which results in the absence of fingerprints.
CC       {ECO:0000269|PubMed:24664640, ECO:0000269|PubMed:26932190}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry. Splice site mutations causing aberrant splicing of skin-specific
CC       isoform 3 are likely to exert a loss-of-function effect and are
CC       involved in BSNS. {ECO:0000269|PubMed:24664640,
CC       ECO:0000269|PubMed:26932190}.
CC   -!- DISEASE: Huriez syndrome (HRZ) [MIM:181600]: An autosomal dominant
CC       syndrome characterized by atrophic fibrosis of the skin of the limbs,
CC       nail hypoplasia, and palmoplantar keratoderma. Malignant degeneration
CC       of affected skin resulting in aggressive squamous cell carcinoma and
CC       early metastasis formation is a distinctive feature of the syndrome.
CC       {ECO:0000269|PubMed:29409814}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 3]: Skin-specific. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the SNF2/RAD54 helicase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH17953.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAA86436.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAB14759.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=The ends of our fingers
CC       - Issue 136 of March 2012;
CC       URL="https://web.expasy.org/spotlight/back_issues/136";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY008271; AAG16639.1; -; mRNA.
DR   EMBL; AB032948; BAA86436.2; ALT_INIT; mRNA.
DR   EMBL; AK023990; BAB14759.1; ALT_INIT; mRNA.
DR   EMBL; AK027490; BAB55150.1; -; mRNA.
DR   EMBL; AK301668; BAH13535.1; -; mRNA.
DR   EMBL; AC096746; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC017953; AAH17953.1; ALT_SEQ; mRNA.
DR   EMBL; BC045534; AAH45534.1; -; mRNA.
DR   EMBL; AL359929; CAB95769.1; -; mRNA.
DR   EMBL; AL512768; CAC21685.1; -; mRNA.
DR   CCDS; CCDS3639.1; -. [Q9H4L7-1]
DR   CCDS; CCDS47101.1; -. [Q9H4L7-2]
DR   CCDS; CCDS58914.1; -. [Q9H4L7-3]
DR   RefSeq; NP_001121901.1; NM_001128429.2. [Q9H4L7-2]
DR   RefSeq; NP_001121902.1; NM_001128430.1. [Q9H4L7-2]
DR   RefSeq; NP_001241878.1; NM_001254949.1. [Q9H4L7-3]
DR   RefSeq; NP_064544.2; NM_020159.4. [Q9H4L7-1]
DR   RefSeq; XP_016863952.1; XM_017008463.1.
DR   PDB; 6H3A; X-ray; 5.50 A; B/D=95-347.
DR   PDB; 6QU1; X-ray; 3.70 A; D=151-198.
DR   PDBsum; 6H3A; -.
DR   PDBsum; 6QU1; -.
DR   AlphaFoldDB; Q9H4L7; -.
DR   SMR; Q9H4L7; -.
DR   BioGRID; 121244; 186.
DR   IntAct; Q9H4L7; 21.
DR   MINT; Q9H4L7; -.
DR   STRING; 9606.ENSP00000351947; -.
DR   GlyGen; Q9H4L7; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9H4L7; -.
DR   MetOSite; Q9H4L7; -.
DR   PhosphoSitePlus; Q9H4L7; -.
DR   BioMuta; SMARCAD1; -.
DR   DMDM; 306526240; -.
DR   EPD; Q9H4L7; -.
DR   jPOST; Q9H4L7; -.
DR   MassIVE; Q9H4L7; -.
DR   MaxQB; Q9H4L7; -.
DR   PaxDb; Q9H4L7; -.
DR   PeptideAtlas; Q9H4L7; -.
DR   ProteomicsDB; 80860; -. [Q9H4L7-1]
DR   ProteomicsDB; 80861; -. [Q9H4L7-2]
DR   ProteomicsDB; 80862; -. [Q9H4L7-3]
DR   Antibodypedia; 14709; 153 antibodies from 26 providers.
DR   DNASU; 56916; -.
DR   Ensembl; ENST00000354268.9; ENSP00000346217.4; ENSG00000163104.18. [Q9H4L7-1]
DR   Ensembl; ENST00000359052.8; ENSP00000351947.4; ENSG00000163104.18. [Q9H4L7-2]
DR   Ensembl; ENST00000457823.6; ENSP00000415576.2; ENSG00000163104.18. [Q9H4L7-2]
DR   Ensembl; ENST00000509418.1; ENSP00000423286.1; ENSG00000163104.18. [Q9H4L7-3]
DR   GeneID; 56916; -.
DR   KEGG; hsa:56916; -.
DR   MANE-Select; ENST00000354268.9; ENSP00000346217.4; NM_020159.5; NP_064544.2.
DR   UCSC; uc003htb.5; human. [Q9H4L7-1]
DR   AGR; HGNC:18398; -.
DR   CTD; 56916; -.
DR   DisGeNET; 56916; -.
DR   GeneCards; SMARCAD1; -.
DR   HGNC; HGNC:18398; SMARCAD1.
DR   HPA; ENSG00000163104; Low tissue specificity.
DR   MalaCards; SMARCAD1; -.
DR   MIM; 129200; phenotype.
DR   MIM; 136000; phenotype.
DR   MIM; 181600; phenotype.
DR   MIM; 612761; gene.
DR   neXtProt; NX_Q9H4L7; -.
DR   OpenTargets; ENSG00000163104; -.
DR   Orphanet; 1658; Absence of fingerprints-congenital milia syndrome.
DR   Orphanet; 384; Huriez syndrome.
DR   Orphanet; 289465; Isolated congenital adermatoglyphia.
DR   PharmGKB; PA134954731; -.
DR   VEuPathDB; HostDB:ENSG00000163104; -.
DR   eggNOG; KOG0389; Eukaryota.
DR   GeneTree; ENSGT00910000144252; -.
DR   HOGENOM; CLU_000315_16_3_1; -.
DR   InParanoid; Q9H4L7; -.
DR   OMA; MEMRRMA; -.
DR   OrthoDB; 5482994at2759; -.
DR   PhylomeDB; Q9H4L7; -.
DR   TreeFam; TF105768; -.
DR   PathwayCommons; Q9H4L7; -.
DR   SignaLink; Q9H4L7; -.
DR   SIGNOR; Q9H4L7; -.
DR   BioGRID-ORCS; 56916; 13 hits in 1169 CRISPR screens.
DR   ChiTaRS; SMARCAD1; human.
DR   GeneWiki; SMARCAD1; -.
DR   GenomeRNAi; 56916; -.
DR   Pharos; Q9H4L7; Tbio.
DR   PRO; PR:Q9H4L7; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q9H4L7; protein.
DR   Bgee; ENSG00000163104; Expressed in adrenal tissue and 173 other tissues.
DR   ExpressionAtlas; Q9H4L7; baseline and differential.
DR   Genevisible; Q9H4L7; HS.
DR   GO; GO:0000792; C:heterochromatin; ISS:UniProtKB.
DR   GO; GO:0043596; C:nuclear replication fork; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:RHEA.
DR   GO; GO:0008094; F:ATP-dependent activity, acting on DNA; IBA:GO_Central.
DR   GO; GO:0140658; F:ATP-dependent chromatin remodeler activity; IMP:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0043130; F:ubiquitin binding; IEA:InterPro.
DR   GO; GO:0006338; P:chromatin remodeling; IMP:GO_Central.
DR   GO; GO:0051304; P:chromosome separation; IMP:UniProtKB.
DR   GO; GO:0000729; P:DNA double-strand break processing; IMP:UniProtKB.
DR   GO; GO:0000018; P:regulation of DNA recombination; IEP:UniProtKB.
DR   CDD; cd17998; DEXHc_SMARCAD1; 1.
DR   CDD; cd18793; SF2_C_SNF; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   Gene3D; 3.40.50.10810; Tandem AAA-ATPase domain; 1.
DR   InterPro; IPR003892; CUE.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR038718; SNF2-like_sf.
DR   InterPro; IPR000330; SNF2_N.
DR   PANTHER; PTHR10799; SNF2/RAD54 HELICASE FAMILY; 1.
DR   PANTHER; PTHR10799:SF964; SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A CONTAINING DEAD/H BOX 1; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   Pfam; PF00176; SNF2-rel_dom; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2.
DR   PROSITE; PS51140; CUE; 2.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Chromatin regulator; Chromosome; DNA damage; DNA repair; DNA-binding;
KW   Ectodermal dysplasia; Helicase; Hydrolase; Isopeptide bond;
KW   Nucleotide-binding; Nucleus; Palmoplantar keratoderma; Phosphoprotein;
KW   Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN           1..1026
FT                   /note="SWI/SNF-related matrix-associated actin-dependent
FT                   regulator of chromatin subfamily A containing DEAD/H box 1"
FT                   /id="PRO_0000074356"
FT   DOMAIN          157..199
FT                   /note="CUE 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00468"
FT   DOMAIN          251..294
FT                   /note="CUE 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00468"
FT   DOMAIN          509..677
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   DOMAIN          858..1010
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00542"
FT   REGION          1..82
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          203..251
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          302..328
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          354..373
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           628..631
FT                   /note="DEGH box"
FT   MOTIF           721..738
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   MOTIF           1005..1008
FT                   /note="DEGD box"
FT   COMPBIAS        44..72
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        223..241
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         521..529
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   BINDING         897..904
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         54
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         57
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         71
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         79
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         124
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:17525332, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         127
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:17525332, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         132
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332"
FT   MOD_RES         146
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         152
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         211
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         214
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         217
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         239
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         242
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         302
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:23186163"
FT   CROSSLNK        77
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        84
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        335
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        471
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        724
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        996
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..430
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043110"
FT   VAR_SEQ         765
FT                   /note="L -> LVT (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10574461,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_007104"
FT   VARIANT         66
FT                   /note="S -> F (in dbSNP:rs11723410)"
FT                   /id="VAR_028037"
FT   VARIANT         135
FT                   /note="L -> F (in dbSNP:rs2664891)"
FT                   /id="VAR_028038"
FT   VARIANT         140
FT                   /note="R -> C (in dbSNP:rs2632398)"
FT                   /id="VAR_028039"
FT   VARIANT         245
FT                   /note="S -> Y (in dbSNP:rs3103117)"
FT                   /id="VAR_028040"
FT   VARIANT         247
FT                   /note="S -> N (in dbSNP:rs11722476)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0007744|PubMed:17081983"
FT                   /id="VAR_028041"
FT   VARIANT         301
FT                   /note="V -> A (in dbSNP:rs7439869)"
FT                   /evidence="ECO:0000269|PubMed:11031099,
FT                   ECO:0000269|PubMed:15489334, ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:23186163"
FT                   /id="VAR_028042"
FT   VARIANT         351
FT                   /note="P -> Q (in dbSNP:rs17854344)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_028043"
FT   VARIANT         972
FT                   /note="V -> A (in dbSNP:rs17857297)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_028044"
FT   MUTAGEN         528
FT                   /note="K->R: No effect on subcellular localization and on
FT                   histone deacetylation."
FT                   /evidence="ECO:0000269|PubMed:21549307"
FT   CONFLICT        215
FT                   /note="E -> D (in Ref. 5; AAH17953)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        937
FT                   /note="N -> D (in Ref. 3; BAB14759)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1026 AA;  117402 MW;  0A5DB5653F478413 CRC64;
     MNLFNLDRFR FEKRNKIEEA PEATPQPSQP GPSSPISLSA EEENAEGEVS RANTPDSDIT
     EKTEDSSVPE TPDNERKASI SYFKNQRGIQ YIDLSSDSED VVSPNCSNTV QEKTFNKDTV
     IIVSEPSEDE ESQGLPTMAR RNDDISELED LSELEDLKDA KLQTLKELFP QRSDNDLLKL
     IESTSTMDGA IAAALLMFGD AGGGPRKRKL SSSSEPYEED EFNDDQSIKK TRLDHGEESN
     ESAESSSNWE KQESIVLKLQ KEFPNFDKQE LREVLKEHEW MYTEALESLK VFAEDQDMQY
     VSQSEVPNGK EVSSRSQNYP KNATKTKLKQ KFSMKAQNGF NKKRKKNVFN PKRVVEDSEY
     DSGSDVGSSL DEDYSSGEEV MEDGYKGKIL HFLQDASIGE LTLIPQCSQK KAQKITELRP
     FNSWEALFTK MSKTNGLSED LIWHCKTLIQ ERDVVIRLMN KCEDISNKLT KQVTMLTGNG
     GGWNIEQPSI LNQSLSLKPY QKVGLNWLAL VHKHGLNGIL ADEMGLGKTI QAIAFLAYLY
     QEGNNGPHLI VVPASTIDNW LREVNLWCPT LKVLCYYGSQ EERKQIRFNI HSRYEDYNVI
     VTTYNCAISS SDDRSLFRRL KLNYAIFDEG HMLKNMGSIR YQHLMTINAN NRLLLTGTPV
     QNNLLELMSL LNFVMPHMFS SSTSEIRRMF SSKTKSADEQ SIYEKERIAH AKQIIKPFIL
     RRVKEEVLKQ LPPKKDRIEL CAMSEKQEQL YLGLFNRLKK SINNLEKNTE MCNVMMQLRK
     MANHPLLHRQ YYTAEKLKEM SQLMLKEPTH CEANPDLIFE DMEVMTDFEL HVLCKQYRHI
     NNFQLDMDLI LDSGKFRVLG CILSELKQKG DRVVLFSQFT MMLDILEVLL KHHQHRYLRL
     DGKTQISERI HLIDEFNTDM DIFVFLLSTK AGGLGINLTS ANVVILHDID CNPYNDKQAE
     DRCHRVGQTK EVLVIKLISQ GTIEESMLKI NQQKLKLEQD MTTVDEGDEG SMPADIATLL
     KTSMGL
//
